Oliver's mTOR Atlas Evidence Platform
Reading level
Mode

Rajesh R. Rao

First author of mouse studies in Protul Shrikant's group showing that mTOR activity decides between effector and memory fates in CD8 T cells by controlling T-bet and Eomesodermin

Department of Immunology, Roswell Park Cancer Institute, Buffalo (papers with Protul Shrikant, 2010–2012)

Rajesh Rao was first author of the Atlas study in which IL-12 raised and prolonged mTOR activity in naive mouse CD8 T cells, and rapamycin blocked sustained T-bet expression, raised Eomesodermin and produced memory-precursor cells that persisted and controlled tumours better after transfer (RAO2010). A 2012 follow-up from the same group, also with Rao as first author, placed the transcription factor Foxo1 downstream of mTORC1 in this switch. The 2010 paper appeared in the same period as studies from other groups linking mTOR inhibition by rapamycin to better CD8 T-cell memory.

PubMed gives his forename as Rajesh. No current institutional page was found that can be tied to this person with confidence, so the affiliation shown is the one on the Atlas paper.

Milestones in the Atlas

A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.

YearEvidenceStudy
2010 M The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin RAO2010 First author: showed in mouse CD8 T cells that sustained mTOR activity drives T-bet and effector fate, while rapamycin favours Eomesodermin and memory precursors.

Co-authors in the Atlas

People with a profile here who share at least one study with Rajesh R. Rao.

Every researcher with a profile →

← All researchers

Was this page useful?
Spotted something wrong or out of date about Rajesh R. Rao?